$125MSeries B, 8 January 2026
Oversubscribed Series B to take lead antibody DIAG723 into first-in-human trial in HHT in H1 2026.
- Amount
- $125M
- Stage
- Series B
- Announced
- 8 January 2026
- Lead
- Sanofi Ventures
- Other investors
- Janus Henderson Investors, Deep Track Capital, EcoR1 Capital, Logos Capital, Balyasny Asset Management, Woodline Partners
- Use of funds
- Oversubscribed Series B to take lead antibody DIAG723 into first-in-human trial in HHT in H1 2026.
- Checked
- Announced by the company
- Sources
- Diagonal Therapeutics: $125 Million Series B Raised To Advance DIAG723 Clustering Antibody Into the Clinic biospace.com
Diagonal Therapeutics: $125 Million Series B Raised To Advance DIAG723 Clustering Antibody Into the Clinic pulse2.com